nhs healthcare contracts

Strengthening Cultural Capability and Trauma Informed Care in Women’s Health The work has a specific focus on three linked problems: women not being listened to, the under recognition and normalisation of procedural pain, and the disproportionate impact of both on women from the Global Majority. Aims and objectives: 1. To improve how the women’s health workforce listens and responds to women, recognises and acts on pain, and delivers culturally competent care. 2. To build lasting training capacity in every NHS England region rather than deliver a one off national course. 3. To give integrated care boards practical guidance so they can sustain local delivery and commission further work in this area themselves. 4. To ensure the programme is shaped by the experience of the workforce and by what women have told NHS England, including women from Global Majority communities and women from the Core20 population. 5. To leave NHS England owning a complete and refreshable set of materials that can be updated as the capability framework develops. The maximum financial envelope for the full duration of the Contract including all extensions this is £175,000.00 (Exclusive of VAT). The initial contract term shall commence upon signing by the authority and conclude 31st March 2027. The Contract may be extended by election of the Contracting Authority, on such notice and for such periods as is specified by the Contract. The Contracting Authority will enter into a contract with 1 provider. The deadline for submission of completed ITT submissions is Friday 30th October 2026 at 12:00pm (midday). Late submissions will not be accepted therefore, please submit in good time prior to the deadline date and time. All communications should be made via the messaging function on the e-Tendering portal during the tender exercise. The Contracting Authority requests that all communications are channelled through the e-portal system and not with the Contracting Authority itself other than as expressly permitted within this ITT. Further information relating to this project can be found at NHSE e-tendering portal at the link below. All clarification questions and submission bids must be received via this portal only. Registration is free of charge. https://health-family-contract-search.secure.force.com/?SearchType=Projects

Planned Preventative Maintenance to our Building Management System (BMS) Trend 963 system

Project title: NHS National Framework for Lenvatinib Offer reference number: CM/TNS/26/5751 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5751 Lenvatinib Lot 1 CESW: 01/06/2027 to 31/01/2029 (20 months) Lot 2 NWLN: 01/06/2027 to 30/09/2028 (16 months) Lot 3 LSNE: 01/06/2027 to 31/05/2028 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Foreign, Commonwealth and Development Office (FCDO) represented by the British High Commission in New Delhi (India) intends to competitively identify (using PA 2023 - Competative Flexiable Procedure) competent Insurance Broker and an Insurance Agency for providing following two General Insurance Products: Product 1: Group Medical Insurance (to cover OPD & IPD) for Staff and their Dependents. Product 2: Group Accidental Insurance cover for Staff (only). Our preference will be to identify and Insurance Agency via a Broker. The Broker will be engaged for a period of 3 years and the Insurance provider for 1 year initially, with the policy period commencing on 1st April 2027. Towards the end of First year, the Broker will help British High Commission in selecting the insurance provider for the following 2 years (1 year at a time).

Supply Chain Coordination Limited (“NHS Supply Chain”) intends to procure a National Framework Agreement for the supply of Medical Examination Gloves including but not limited to: 6N Examination Gloves: 6N Nitrile Exam Gloves Examination Gloves Specialised Following further review of the category strategy, market landscape, and customer requirements, it has been concluded that Medical Examination Gloves and Surgical Gloves will be procured through separate frameworks. Whilst the original PME notice (2025/S 000-052117) indicated an intention to combine the two categories into a single framework, subsequent analysis identified that they operate as distinct markets with differing customer needs, supply bases, technical specifications, and procurement considerations. In addition, the categories are subject to different commercial models, pricing mechanisms, market dynamics, and contract management requirements. Maintaining separate frameworks will enable a more tailored procurement approach for each category, support effective category management, and better align with customer and market needs. This revised approach is expected to enhance supplier engagement, promote competition, and provide greater flexibility to respond to future market developments and evolving customer demand. We are looking at ways to review the procurement strategy and simplify commercials in terms of agreements and pricing points, rationalise ranges for stocked product. This framework will continue to incorporate sustainability requirements for third party social audits across Medical Examination Gloves. NHS Supply Chain is assessing the most appropriate procurement approach, and the tendering procedures that may be used for future contract awards. The Framework Agreement will be entered into between the Authority and individual Supplier(s). The Authority may purchase goods under the Framework Agreement, which will be made available for purchase by: • any NHS Trust; • any other NHS entity; • any government department, agency or other statutory body (for the avoidance of doubt including local authorities); and/or • any private sector entity active in the UK healthcare sector. The award of a place on the Framework Agreement does not guarantee any commitment by the Authority or its customers to place any orders under the Framework Agreement. To participate in NHS Supply Chain procurements, Tenderers must be registered on the Central Digital Platform (CDP) and have shared their information with NHS Supply Chain via the CDP. The CDP is available at: https://www.gov.uk/findtender Please ensure your details match your account details in Jaggaer, Companies House and CDP. It is the Suppliers responsibility to ensure the account set up in Jaggaer is in the correct company name. For example, if the name has been set up incorrectly or the business has had changes to its organisation we recommend the following: Incorrect Name (such as typo) - Contact Jaggaer via the help options (seen on page after logging in) and explain that the details are incorrect and provide correct details. Company organisation Changes - 2 options: Note: Audit trails need to be maintained in Jaggaer which makes it difficult to allow changes to business that have had significant changes such as merges of businesses or been purchased by other organisations. Option 1: Create a new account with new name (preferred). Option 2: Current account - Contact Jaggaer via the help options (seen on page after logging in) and provide details of the changes (such as a company name change document from companies house). Tenderers must also be registered on Jaggaer, as all tender activity will be conducted through this system. The Tenderer is responsible for ensuring that its Jaggaer account is set up in the correct company name and that all information is kept up to date. Jaggaer can be accessed via https://nhssupplychain.app.jaggaer.com The Authority estimates that, in the first 12 months of the Framework, the total value of purchases will be approximately £125,000,000 excluding VAT. Over the full 48-month term, the estimated total value is approximately £500,000,000 excluding VAT. These values are indicative only and do not constitute any guarantee of business with successful Tenderers. The following requirements are anticipated to apply but are not exhaustive and may be updated in accordance with applicable legislation and/or relevant guidance (please refer to the requirements set out in the ITT): • ISO Certification Tenderers must hold ISO 9001: 2015, ISO 13485:2016 or Medical Device Single Audit Program (MDSAP) certification, accredited by the United Kingdom Accreditation Service (UKAS) or internationally recognised equivalent. The certification must cover all relevant elements of the Tenderer’s and the product(s)’ supply chain, including (but not be limited to) sales, manufacturing, storage and distribution. Acceptable UKAS alternatives are listed at: https://global-aci.org/en/full-members • CE Certification and Declaration of Conformity Where applicable, valid CE Certification and Declarations of Conformity must be submitted at the tender submission stage. • Modern Slavery Statement Tenderers with an annual turnover of £36 million or more must comply with the Modern Slavery Act 2015, publish an annually updated Modern Slavery Statement on their website, and provide a link to that statement. • Modern Slavery Assessment Tool (MSAT) Tenderers must have achieved an MSAT score of 41% or above within 12 months prior to the tender close date. The assessment results must be shared with NHS Supply Chain via the ‘share’ function on the Supplier Registration Service (SRS) Portal, available at: https://supplierregistration.cabinetoffice.gov.uk • Third-party Audit Tenderers must provide evidence of third-party social audits for manufacturing facilities supplying products under the Framework. Audit requirements are expected to include assessment against forced labour risks, including the 11 International Labour Organisation (ILO) Forced Labour Indicators. NHS Supply Chain continues to review its responsible sourcing approach and, as such, third-party audit requirements may be developed further during the procurement process. Further details will be provided within the ITT documentation. • Evergreen Sustainable Supplier Assessment Tenderers must have completed the Evergreen Sustainable Supplier Assessment and achieved Level 1 or above within 12 months prior to the Tender Close Date. Guidance and access are available at: https://www.england.nhs.uk/nhs-commercial/central-commercialfunction-ccf/evergreen • Carbon Reduction Plan (CRP) Tenderers must provide a valid Carbon Reduction Plan (CRP) link on their website that meets the requirements of PPN 006. • Cyber Security Tenderers that handle patient or personal data, or provide IT systems, services, or devices, must either: • hold a valid Cyber Essentials Plus Certificate; or • where the Tenderer does not have a Cyber Essentials Plus Certificate, submit a completed Information Security Third Party Questionnaire (ISTPQ). • Distribution Agreements If tendering as a Distributor, the Tenderer must provide written evidence from the relevant Original Equipment Manufacturer(s) (OEM) confirming that they have rights to distribute goods for the Term as defined in the Framework Agreement Award Pack. If the Term is extended, Distributors must provide further written evidence from the OEM confirming that they have rights to distribute goods for the remaining Maximum Term as defined in the Framework Agreement Award Pack.

NHS South West London Integrated Care Board (the Authority) is seeking to commission a Mental Health Support Team (MHST) service comprising 25 operational and developing MHSTs across the six boroughs. The service will provide prevention and early intervention mental health support through a standardised and equitable MHST offer, in accordance with the specified requirements, to improve access to care, reduce health inequalities, and deliver improved outcomes for children and young people across South West London. Procured through a competitive process under the Health Care Services (Provider Selection Regime) Regulations 2023, the Authority intends to appoint a Lead Provider with overall accountability for the governance, management, and delivery of the service. The Lead Provider will oversee all operational and developing MHSTs across South West London and will be responsible for the mobilisation, delivery and service integration of future MHST teams required as part of the planned expansion to achieve 100% MHST coverage across South West London by December 2029. The decisions applicable to this Procurement will be made by the Authority. The Procurement is being managed by NHS London Commercial Hub (NHS LCH) hosted by NHS North East London, on behalf of the Authority, in connection with an Invitation to Tender (ITT) exercise that is being conducted, based on the competitive process under the Health Care Services (Provider Selection Regime) regulations 2023 ("the Regulations"(as amended). None of the references to "ITT", "Bid", or the use of the term "tender process", or any other indication, shall be taken to mean that the Authority intends to hold itself bound to any of the Regulations, save those applicable to PSR provisions regarding the Competitive Process. Further information regarding the Authority is available from: https://www.southwestlondon.icb.nhs.uk/ The lifetime Value of the contract is £89,916,960 excluding VAT. The contract term is for three (3) years with an option for extension of further three (1 + 1 + 1) years at the sole discretion of the Authority. The contract will start on 01/04/2027 and end 31/03/2030, if the 1 + 1 + 1 optional extensions are utilised the maximum contract end date will be 31/03/2033. The maximum duration of the contract is 6 years (72 months). Further details of the procurement, including service requirements are included in the procurement documents.

The Trust invites quotations for the supply and delivery of 11 new mobile patient hoists for use in an inpatient setting. The hoists must support transfers between beds, chairs and wheelchairs, have a base suitable for use beneath low beds, and have a minimum safe working load of 130 kg. With a powered lifting system Delivery will be to Orsett Hospital, Rowley Road, Grays, RM16 3EU. Quotations must include all delivery charges to this location.

The primary objective of the Service is to provide a proactive, responsive, and effective pest management programme that minimises pest-related risks, supports infection prevention and control objectives, protects the Trust’s assets and reputation, and maintains a safe and welcoming environment for patients, staff, visitors and Suppliers.

The contract is expected to initially be delivered for NHS-funded care in England and Wales, and publicly funded care in Jersey for a period of three years, at a maximum total budget of up to £933,979.20 GBP including VAT and £778,316.00 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years as well as the option to include other Devolved Nations and/or Crown Dependencies, aspirational measures and discretionary inflationary uplifts (all of which will be defined in the service specification). The maximum budget ‘core’ value of £933,979.20 GBP including VAT and £778,316.00 GBP excluding VAT, excludes the potential two-year extension and aspirational intent as included in section 14.4 of Annex A - Service Specification The contract may be extended for up to 24 months at a pro rata value of the core three- year funding, estimated at up to £518,877 excluding VAT. This proposed extension value may also include pro rata funding of any additional aspirational measures invoked in the first three years of the contract. For example: If an aspirational annual requirement costing £500,000 per year is invoked in year three, then the extension funding (if the aspirational measure is continued) will be the above figures plus the additional £500,000 per year. Further to this funding, the specification contains a list of aspirational measures which will be expected to be modified into the contract should the need and funding become available. The aspirational intent value, including the potential two- year extension and core 3 year value means an overall ceiling value for this contract of up to £6,417,788 excluding VAT and £7,701,346 including VAT. This aspirational intent has the potential to be invoked fully, partially, or not at all, and the Authority cannot guarantee that the successful supplier will be required to do any of the aspirational measures listed in section 14.4 of Annex A - Service Specification The role of a national clinical audit is to stimulate healthcare quality improvement through the provision of high-quality information on the organisation, delivery and outcomes of healthcare, together with tools and support to enable healthcare providers and other audiences to make best use of this information. Outcomes are benchmarked against available national guidance and standards e.g. quality standards from the National Institute for Health and Care Excellence (NICE), and those from other established professional and patient sources. Successful national audits are those where the individuals who are engaging with and using the audit results are also in a position to improve the system, and where there is a shared understanding of what good care looks like. National clinical audits are expected to: a.Develop a robust, high-quality audit designed around key quality metrics likely to best support local and national healthcare quality improvement. b.Detect, describe and help reduce unwarranted clinical variation by systematically benchmarking performance, identifying outliers, and supporting services to understand variation in outcomes, processes and experience. c.Achieve, articulate and maintain close alignment with relevant NICE national guidance and quality standards throughout the audit, as appropriate. d.Enable healthcare quality improvement through the provision of timely, high-quality data that compares providers of healthcare, and comprises an integrated mixture of named Trust or Health board, Integrated Care System (ICS), commissioner, multidisciplinary team (MDT), possibly consultant or clinical team level and other levels of reporting. e.Engage patients, carers and the public in a meaningful way, achieving a strong patient voice which informs and contributes to the design, functioning, outputs and direction of the audit. f.Consider the value and feasibility of linking data at an individual patient level to other relevant national datasets either from the outset or in the future and plan for these linkages from the inception of the contract. g.Ensure robust methodological and statistical input at all stages of the audit. h.Identify from the outset the full range of audiences for the reports and other audit outputs and plan and tailor them accordingly. i.Provide audit results in a timely, accessible and meaningful manner to support healthcare quality improvement, minimising the reporting delay and providing continual access to each unit for their own data. j.Utilise strong and effective project and programme management to deliver audit outputs on time and within budget. k.Develop and maintain strong engagement with local clinicians, networks, commissioners, patients and their families and carers and charity and community support groups to drive improvements in services. l.Deliver high-quality audit outputs, benchmarking and quality improvement as a priority. At the time of writing the specification, requirements include (but please also refer to the potential future aspirational intent section): 1. Audit Purpose The overall ambition of the audit is to continue to capture and report data on the performance of individual healthcare providers against the National Institute for Health and Care Excellence (NICE) Quality Standard QS33: Rheumatoid Arthritis in Adults, Quality standard QS214: Rare diseases, and other relevant national standards and guidance, (see Appendix 1). 2. Paediatric Inflammatory Arthritis Pathway The supplier should work with the wider Dataset and Methodology Stakeholder Group to develop, maintain and report against a minimum viable paediatric inflammatory arthritis pathway. The initial focus should be on establishing a clinically meaningful dataset and reporting framework sufficient to describe the patient pathway and support audit activity. Initial measures should focus on a limited number of priority areas agreed with funders and stakeholders, for example referral, diagnosis and treatment timelines. The updated GIRFT Paediatric Inflammatory Arthritis Pathway guidance, anticipated for publication in January 2027, should be considered a key reference for the future development of the dataset, measures and reporting framework. The supplier should work with the wider Dataset and Methodology Stakeholder Group to review and align the dataset, metrics and reporting outputs with the recommendations and standards set out within the GIRFT guidance, ensuring ongoing relevance and consistency with national best practice. Any expansion beyond the core pathway, including additional metrics, PROMs/PREMs, transition measures and broader pathway development, should be considered future aspirational intent subject to feasibility, resources and further funding. 3. Data Collection and Audit Design The supplier should continue to deliver a continuous prospective clinical audit and work with the Dataset and Methodology Group to ensure the audit dataset remains clinically relevant and proportionate. The supplier is expected to collaborate with specialist disease-specific clinical groups to support interpretation of findings and improve case ascertainment and recruitment rates. 4. Organisational Survey and Quality Improvement The supplier should review and maintain the organisational survey to ensure it remains proportionate and aligned with audit objectives. Priority should be given to maximising analysis and utilisation of existing data rather than increasing data collection burden in collaboration with the wider Dataset and Methodology Stakeholder Group. The organisational survey should support the audit's quality improvement objectives by enabling a deeper understanding of service delivery, workforce capacity, variation in practice and barriers to high-quality care. 5. Benchmarking and Improvement The audit is expected to support continuous improvement across all services. While identifying high-performing and outlier services remains important, the audit should also support improvement among services performing at or around the national average, where the greatest overall gains may be achieved. Benchmarking should encourage year-on-year improvement within individual services and provide meaningful insights that motivate all providers to improve, regardless of their current position relative to national performance. 6. Targeted improvement support The supplier should provide targeted quality improvement support following each annual audit cycle. Activities should build on existing professional networks, collaboratives and stakeholder infrastructure wherever possible rather than creating wholly new arrangements. Improvement support should be designed to benefit healthcare providers across the performance spectrum, including those performing at a middle level where the greatest overall gains may be achieved, while also supporting services experiencing significant challenges or demonstrating exceptional practice. Learning generated through quality improvement activities should be shared with all participating healthcare providers to maximise the impact of the audit programme. The anticipated outputs are: 1.Near real-time dynamic and interactive metric results. 2.Publication of an annual state of the nation report with the inclusion of an organisational survey. 3.Incorporation of validated Patient Reported Outcome Measures. 4.Quality improvement resources. 5.The identification and notification of outliers. For further information on the current audit, currently delivered by the British Society for Rheumatology (BSR) please head to: https://www.rheumatology.org.uk/improving-care/audits/neiaa

Non-exclusive framework agreement for the supply of Medical Pulp Associated Products via the Stock, eDirect and Direct route to market. This includes but is not limited to; a range of products that are used to assist with the toileting of patients, collection of samples and aid the administration of procedures. The ranges of products available under the framework agreement include; Disposable Medical Pulp, Medical Pulp support products, Macerators, Bedpan Washers and Absorbent products for use with Medical Pulp. This framework agreement is for a total of 48 months. Precise quantities are unknown, however, it is anticipated that expenditure will be in the region of £120,000,000 ex VAT / £144,000,000 inc VAT throughout the duration of this framework agreement. This is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.

The Local Government Association (LGA) is seeking a supplier to undertake a focused policy research project exploring the interaction between NHS Continuing Healthcare (CHC) and local authority adult social care. Recent evidence has highlighted growing concerns about the relationship between CHC decision-making, adult social care expenditure and the incentives created by current funding arrangements. ADASS's Spring Survey 2026 found that 75% of Directors of Adult Social Services reported an increase in the number of people presenting to adult social care who were, or previously would have been, eligible for CHC, while 84% reported that Integrated Care Board (ICB) disinvestment in CHC was contributing to adult social care overspending pressures. Research published by The King's Fund found that CHC eligibility rates have fallen significantly despite no change to the national eligibility framework, alongside substantial variation between different ICB areas. While CHC provides the primary lens for this project, the LGA is also interested in the wider question of whether current funding and accountability arrangements across health and social care create incentives that transfer costs and risks between organisations rather than supporting whole-system decision making. The LGA wishes to better understand: • How these issues are playing out locally • Whether current arrangements create misaligned incentives between organisations • The impact on local government, the NHS, people drawing on care and support, and unpaid carers • What reforms could improve alignment between health and social care funding and accountability. This work will inform future LGA policy development and engagement with government, national partners and stakeholders.

Procurement of quality assurance and improvement of GP Specialty Training structured learning placement modules to support trainee capacity and curriculum delivery.

ergonomic standing and raising aid that mobilises residents/patients during everyday activities, such as transfers and toileting and we need 3 of these items

Independent evaluation of the Solar and battery storage scheme delivered through the NHS in England. The evaluation will assess the impact, delivery and value for money of capital investment in solar PV and associated battery storage at NHS sites, including the extent to which funded projects reduce carbon emissions, lower energy costs, improve on-site energy generation and strengthen energy resilience.

NHS England is seeking a supplier to provide ongoing maintenance, administration and operational support for the National Competency Framework (NCF) for Data and Analytics Professionals. The NCF is a nationally adopted framework that defines the knowledge, skills and behaviours required across the health and care system and supports workforce capability development, career progression, professional standards and associated workforce products. The appointed supplier will provide day-to-day support to ensure the framework remains current, accessible and effective for existing and prospective users. Activities are expected to include framework maintenance and updates, stakeholder engagement, adopter support, communications, reporting, governance administration and the management of queries and feedback from users. The supplier will also support the promotion and adoption of the framework across NHS organisations and the wider health and care sector. This requirement will provide interim support while NHS England considers the future operating model for the framework, helping to safeguard the continued use, relevance and value of this national workforce asset. Through the delivery of this service, the supplier will support NHS England's wider ambition to build a sustainable, capable and recognised Digital, Data and Technology (DDaT) workforce and enable the continued development of workforce capability across the health and care system.

Provision of Rubidium Generator and Delivery System

In 2021, the NHS Public Board approved a roadmap to drive supplier decarbonisation and support the achievement of the NHS Net Zero target. The 2028 milestone of this roadmap outlines new requirements to be introduced overseeing the provision of carbon footprints for individual products supplied to the NHS. The 2025 Five years of a greener NHS progress report refined the scope of this milestone to high-emission areas, particularly pharmaceuticals, medical technologies, and digital where more granular carbon insights can deliver value on the NHS’s journey to net zero. There isn’t currently a single methodology to measure product level emissions, and further work is required to define the technical approach that will deliver the expected benefits of this policy. This procurement exercise outlines the need to commission a third party with expertise and experience in Product Carbon Footprinting (PCF) in the health sector to support, by the end of Q4 26/27, the selection, tailoring and testing of the technical PCF requirement of the 2028 milestone. This includes working with a technical reference group (TRG) with experts in Footprinting to identify existing methods and standards, assessing their alignment against the NHS policy intentions, recommending options and how they could be practically applied in the identified areas, and testing them with suppliers, using real data, and reporting learnings from the process. Enabling the collection of granular data for high-emission areas is key to assisting NHS England (NHSE) to demonstrate regard to the need to contribute towards compliance with its statutory climate change duties (Climate Change Act 2008 and Environment Act 2021). This project will support understanding of key products’ emissions, allowing the NHSE team and local stakeholders to prioritise actions to tackle supply chain emissions, as well as identifying opportunities for UK innovation and growth, improving health products value and supply resilience.

Provision of medical Gas pipeline authorising engineer

NHS England is seeking a supplier to undertake an independent, evidence-led review of the National Competency Framework (NCF) for Data Professionals. The NCF is a nationally recognised framework that defines the knowledge, skills and behaviours required by data and analytics professionals across the NHS and wider public sector and is intended to support workforce development, professionalisation, career progression and organisational workforce planning. The purpose of this review is to establish a clear understanding of the current awareness, adoption and use of the NCF, assess available evidence of its impact and benefits, and identify the factors that support or hinder adoption across the health and care system. The review will also provide NHS England with a robust evidence base to inform future investment, decision-making and development of the framework. The appointed supplier will be expected to undertake a mixed-methods review, drawing on quantitative and qualitative evidence from relevant stakeholders, users and organisations. The work will include assessing adoption levels, evaluating available evidence of impact and value, gathering stakeholder insights, identifying barriers and enablers to implementation, and developing practical recommendations for future monitoring, evaluation and reporting. The project will deliver an adoption baseline, impact assessment, stakeholder findings, a monitoring and evaluation framework, and evidence-based recommendations. Through this work, the supplier will support NHS England's ambition to build a sustainable, capable and recognised Digital, Data and Technology (DDaT) workforce and strengthen the evidence base underpinning workforce professionalisation across the health and care system.

NHS England (NHSE) are commencing a tender process to identify a supplier who has the capability, capacity and the expert knowledge to support the assessment for GMTS virtual Assessment Centre for the following September intake for 2027 to 2029. This opportunity supports the future generation of NHS Leaders and the contract will enable the annual NHS GMTS Virtual Assessment Centres which are the final recruitment stage delivering high potential non clinical graduate pipeline to NHS organisations and ultimately delivering the 10 year health plan. The assessment part occurs between January to March for each subsequent year in support of each September intake for 2027, 2028 & 2029. The maximum financial envelope for this procurement exercise is £534,780.00 exclusive of VAT (£641,736.00 Inc. VAT). The initial duration of contract will be for twelve (12) months with two optional extension of twelve (12) month & four (4) month. The deadline for completed ITT submissions will be 10th November 2026 at 12:00noon (midday). Late submissions will not be accepted therefore, please submit in good time prior to the deadline date and time. All communications should be made via the messaging function on the e-Tendering portal during the tender exercise and not with the Contracting Authority itself other than as expressly permitted within this ITT.